ArticleMicrobiology spectrum2022
Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Pharmacokinetic/pharmacodynamic target attainment of eravacycline in a liver transplant recipient with refractory VREAntimicrobial agents and chemotherapy · 2026Article
- Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study.Frontiers in pharmacology · 2026Article
- Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.Antimicrobial agents and chemotherapy · 2025Review
- Enterococci-related healthcare-associated ventriculitis and meningitis: a multicenter retrospective case series from clinical practice.BMC neurology · 2025Article
- Resistance mechanisms and tedizolid susceptibility in clinical isolates of linezolid-resistant bacteria in Japan.JAC-antimicrobial resistance · 2025Article
- Genomic insights into the spread of methicillin-resistant Staphylococcus aureus involved in ear infections.BMC infectious diseases · 2025Article
- The latest research progress on the clinical application of nemonoxacin.Frontiers in medicine · 2025Review
- Predicting Drug Resistance: The Use of Novel Inflammatory Markers in Identifying ESBL-ProducingJournal of inflammation research · 2025Article
- Repurposed Anti-Multiple Sclerosis Drug Fty720 Targets Carbapenem-Resistant Acinetobacter baumannii via Multiple Pathways.Current microbiology · 2024Article
- Pathogen Distribution, Drug Resistance Risk Factors, and Construction of Risk Prediction Model for Drug-Resistant Bacterial Infection in Hospitalized Patients at the Respiratory Department During the COVID-19 Pandemic.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.